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HIV-1C is the most prevalent subtype of HIV-1 and accounts
for over half of HIV-1 infections worldwide. Host genetic influence
of HIV infection has been previously studied in HIV-1B, but little
attention has been paid to the more prevalent subtype C. To un-
derstand the role of host genetics in HIV-1C disease progression, we
perform a study to assess the association between longitudinally col-
lected measures of disease and more than 100,000 genetic markers
located on chromosome 6. The most common approach to analyz-
ing longitudinal data in this context is linear mixed effects models,
which may be overly simplistic in this case. On the other hand, exist-
ing non-parametric methods may suffer from low power due to high
degrees of freedom (DF) and may be computationally infeasible at
the large scale. We propose a functional principal variance compo-
nent (FPVC) testing framework which captures the nonlinearity in
the CD4 and viral load with potentially low DF and is fast enough to
carry out thousands or millions of times. The FPVC testing unfolds
in two stages. In the first stage, we summarize the markers of disease
progression according to their major patterns of variation via func-
tional principal components analysis (FPCA). In the second stage, we
employ a simple working model and variance component testing to
examine the association between the summaries of disease progres-
sion and a set of single nucleotide polymorphisms. We supplement
this analysis with simulation results which indicate that FPVC test-
ing can offer large power gains over the standard linear mixed effects
model.
1. Introduction. An important goal of large-scale genomic association studies is to explore sus-
ceptibility to complex diseases. These studies have led to identification of many genomic regions as
putatively harboring disease susceptibility alleles for a wide range of disorders. For patients with a par-
ticular disease, association studies have also been performed to identify genetic variants associated with
progression of disease. The disease progression is often monitored by longitudinally measured biological
markers. Such longitudinal measures allow researchers to more clearly characterize clinical outcomes
that cannot necessarily be captured in one or even a few measurements.
We are motivated by a large-scale association study of HIV-1 Subtype-C (HIV-1C) progression in
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2sub-Saharan African individuals. HIV-1C is the most prevalent subtype of HIV-1 and accounts for over
half of HIV-1 infections worldwide [11]. Sub-Saharan Africa, where HIV-1C dominates, was home to an
estimated 69% of people living with HIV in 2012 [29]. While a number of human leukoucyte antigen
(HLA) alleles [10, 30, 19, e.g.] and other loci have been identified to be associated with AIDS progression
in European males infected by HIV-1B [10, 22], comparatively little research has focused on host genetic
influence in this African population and subtype.
In this study, we seek to relate the longitudinal progression of these two markers – log10 CD4 (lCD4)
count and log10 viral load (lVL) – to a set of approximately 100,000 single nucleotide polymorphisms
(SNPs) located on chromosome 6 in two independent cohorts of treatment-naive individuals in Botswana.
We focus on chromosome 6 because it houses the HLA region of genes, which are known to impact
immune function. Throughout this paper, we will use y = (y1, ..., yr)
T to denote the longitudinal outcome
(in the context of this study, either lCD4 or lVL), measured at times t = (t1, ..., tr)
T. We will furthermore
let a set of genetic markers of interest be denoted z and any potential covariates be x.
The most common approach to analyzing longitudinal data of this kind is to use linear mixed effects
(LME) models [16], which relate y linearly to z, x, and t with both fixed and random effects. However,
both in the case of HIV progression measured by lCD4 and lVL and in general, such a linear relationship
is likely to be overly simplistic. To incorporate nonlinear trajectories, many generalizations of LMEs
have been proposed. Typically, methods assume that y is a noisy realization of a smooth underlying
function Y (·). These include nonlinear or nonparametric LMEs using a fixed spline basis expansion
[18, 25, 12] for t and adjusting for z. Functional regression methods have been proposed for densely
sampled trajectories [6] for a single z as well as for irreguarly spaced longitudinal data where z is also
allowed to change over time [33]. In these methods, estimation proceeds via kernel smoothing for both
the population mean function and the covariance process of Y (·). [15] proposed an iterative procedure for
fitting functional regression models which accounts for within-subject covariance but does not estimate
random effects. Similarly, [23] proposed a ridge-based estimator for the case when y is measured on a
common, fine grid of points for all subjects, but requires z to be univariate and also ignores random
effects. In a similarly dense setting [20] proposed wavelet-based mixed effects models, and inference
procedures for the random effects were developed in [2].
While some of these methods can be adapted to test for association, none of them are appealing
for our study for the following reasons. First, some require restrictive assumptions about the density
of measurements [20, e,g] which are clearly not met here. Further, all of these methods were devel-
oped with estimation and regression in mind. While many of them could in principle be used to derive
testing procedures, the validity of their inference procedures often rely on the model assumptions on
the distribution of y given the SNPs and the covariates. Under model mis-specification, the resulting
test may fail to maintain type I error. Additionally, these procedures would require fitting a complex
iterative or smoothing-based model thousands or millions of times for genome-wide studies and hence
become computationally infeasible. We, on the other hand, propose a novel testing procedure which is
valid regardless of the true distribution of y, is fast to fit and has a simple limiting distribution, despite
the fact that we account for nonlinearity in y in a manner akin to previous functional regression meth-
ods. To do this, we first capture the nonlinearity in y using functional principal components analysis
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(FPCA) [5, 24, 32, 13, 15], Using a eigenfunction decomposition of the smoothed covariance function of
Y (·), we approximate each patient’s Y (·) by a weighted average of the estimated eigenfunctions, with
weights corresponding to functional principal component loadings or scores. Then borrowing a variance
component test framework and using these scores as pseudo outcomes, we construct a Functional Prin-
cipal Variance Component (FPVC) test that can capture the nonlinear trajectories without requiring a
normality assumption or fitting individual functional regression models. The test statistics can be ap-
proximated by a mixture of chi-square and the small number of eigenfunctions needed to approximate
the trajectories can result in a low degree of freedom in the resulting test statistic.
Since the data of interest is sampled at irregular time intervals, we use the best linear unbiased predic-
tor (BLUP) to estimate the scores. The BLUP was also the basis for FPCA with sparse longitudinal data
in the principal analysis via conditional expectation (PACE) method [32] under a normality assumption.
Here, we use BLUP to motivate our testing procedure but do not require normality for the validity of
the FPVC test. The test statistic can be derived through the variance component testing framework and
viewed as a summary measure of the overall covariance between the estimated subject-specific scores,
which characterize the person’s trajectory, and the genetic markers. Similar variance component tests
have previously been proposed for standard linear and logistic regressions with observed single outcomes
[31].
The primary virtues of FPVC testing are threefold. First, we separate the procedure into two stages of
distinct complexity in order to make it feasible at large scale. In the first stage, we model y flexibly using
FPCA and obtain a succinct summary of disease progression for each patient, once and for all. In the
second stage, we perform a rather simple model at large scale. Thus, we segregate the computationally
complex stage (which need occur only once) from the large-scale stage (which could require the same
computation on the order of millions of times in, e.g., genome-wide association studies). Second, the
summary of y that we obtain from FPCA is the most succinct summary possible, as the eigenfunctions
identified by FPCA are the functions that explain the most variability in y. Third, our theoretical
results suggest that the null distribution of the FPVC test statistic reduces to a simple mixture of
χ2 distributions. The variability due to estimating the eigenfunctions does not contribute to the null
distribution of the test statistic asymptotically at the first order (see (11) and the derivation of the
asymptotic null distribution).
The structure of the rest of the paper is as follows. In section 2, we describe FPCA and introduce
FPVC testing and our main theoretical results. In section 3, we give details about the association study
for HIV progression. In section 4, we discuss simulation results, and in section 5 we discuss further
implications of our procedure.
2. Functional principal variance component testing.
2.1. The test statistic. In this section, we propose a testing procedure for assessing the association
between a set of genetic markers z and a longitudinally measured outcome y, adjusting for covariates
x. Let the data for analysis consist of n independent random vectors V = {Vi = (yTi , tTi , zTi ,xTi )T}ni=1,
where yi = (yi1, ..., yiri)
T is a vector of outcome measurements taken at times ti = (ti1, ..., tiri)
T ∈ T ri ,
T is a closed and bounded interval, zi = (zi1, ..., zip)T is a vector of genetic markers of interest, and
4xi = (1, xi1, ..., xiq)
T is a vector of additional covariates that are potentially related to the outcome, all
measured on person i. For each i, we take (zTi ,x
T
i )
T to be distributed as (zT,xT)T.
Our goal is to test the null hypothesis
(1) H0 : yi ⊥ ziS | xi
where ziS = (zij1 , ..., zijs)T is a set of genetic factors to test, identified by the index set S = {j1, ..., js} ⊂
{1, ..., p}. Special cases include marginal testing, as in traditional genome-wide association studies, where
S = {j} for some j ∈ {1, ..., p}, or set-based testing where S are the indices of the SNPs in a gene or
some other related set.
To model the longitudinal trajectory, we assume that yir is a noisy sample of a smooth underlying
function Yi(·), evaluated at the point tir,
yir = Yi(tir) + ir,
which following the logic of [32] can be written as a linear combination of its population mean E{Y (·)}
and a set of K eigenfunctions {φk(·)}
yir = µ(tir) +
K∑
k=1
ξikφk(tir) + ir.(2)
where ξik is the FPCA score associated with the kth eigenfunction, E(ξik) = 0,Var(ξik) = λk, and
the eigenfunctions are ordered such that the kth explains the kth most variance in Y (·). Thus, the
relationship between yi and xi and zi must be captured by the only random quantity in (2), the
random coefficients {ξik}Kk=1. Therefore, testing (1) is equivalent to testing
H0 : {ξik}Kk=1 ⊥ ziS | xi.
However, direct assessment of the association between {ξik}Kk=1 and ziS is difficult since {ξik}Kk=1 are
unobservable and K could be infinity.
Most methods of estimating a function like Yi(·) require an explicit tuning of the smoothness of the
resulting estimator. Here that corresponds to choosing a (typically small) number K of eigenfunctions
as an approximation
Yi(t) ≈ µ(t) +
K∑
k=1
ξikφk(t),
where K < ∞ could be chosen such that the first K directions capture a proportion of the variation
at least as large as ℘ ∈ (0, 1]. Our simulation results (see section 4) suggest that the performance of
FPVC testing is not very sensitive to the choice of K provided that ℘ is close to 1. Since {ξik}Kk=1 are
not observable or generally estimable due to sparse sampling of measurement times, we instead infer
about the association between Yi(·) and zi based on the best linear unbiased predictor (BLUP),
ξ˜ik = λkφ
T
ikΣ
−1
yi (yi − µi)(3)
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where φik = {φk(ti1), ..., φk(tiri)}T,µi = {µ(ti1), ..., µ(tiri)}T, and Σyi = Cov(yi,yi) such that (Σyi)rl =
G(tir, til) + σ
2δrl, Cov{Y (s), Y (t)} = G(s, t), and δrl = I{r=l}. In the PACE method of [32], ξ˜ik was
obtained as E(ξik|yi) under the assumption that ξik and ir are jointly normal, but we don’t require nor-
mality here. We simply take ξ˜ik as an observable and reasonable approximation to ξik even if normality
does not hold, as has been argued in [26] and [14].
Thus, we propose to test (1) by testing
H†0 : {ξ˜ik}Kk=1 ⊥ ziS | xi.
Taking note that the association we seek to test is conditional on x, one may construct a test for H†0
by regressing ξ˜i = (ξ˜i1, ..., ξ˜iK)
T onto (xi, ziS). However, this is only valid if the effect of xi on Yi(·) is
captured fully based on the model relating xi and ξ˜i, which may not be true in general. To remove the
effect of xi without imposing a strong assumption on how xi affects Yi(·), we instead choose to model
the conditional expectation of zij given xi, µzj (xi) = E(zij |xi), and center ziS as z∗iS = (z∗ij1 , ..., z∗ijs)
where for any j
z∗ij = zij − µzj (xi).
To form the test statistic for H0, we propose to summarize the overall association between Y (·) and
zS based on the Frobenius norm of the standardized covariance between ξ˜i and z∗iS
Q0 =
∥∥∥∥∥n− 12
n∑
i=1
ξ˜iz
∗T
iS
∥∥∥∥∥
2
F
.(4)
Though Q0 takes a simple form and can be motivated naturally as an estimated covariance (and can thus
be considered model-free), it can also be viewed as a variance component score test statistic similar to
those considered previously for other regression models [8, 17]. Details on the derivation of the variance
component score test statistic are given in section 2.2.
Both ξ˜i and z
∗
iS involve various nuisance parameters that remain to be estimated. First, under mild
regularity conditions which are outlined in the supplementary article [1], we can use FPCA to estimate
the relevant quantities via local linear smoothing as in [13] and [32]. Subsequently, we can estimate ξ˜ik
by
ξ̂ik = λ̂kφ̂
T
ikΣ̂
−1
yi (yi − µ̂i)(5)
for φ̂ik = {φ̂k(ti1), ..., φ̂k(tiri)}T, µ̂i = {µ̂(ti1), ..., µ̂(tiri)}T, and
(
Σ̂yi
)
rl
= Ĝ(tir, til) + σ̂
2δrl. To estimate
µzj (xi), various approaches can be taken depending on the nature of x. For example, when x is discrete,
µzj (xi) can be estimated empirically. With continuous x, we may impose a parametric model with
(6) µzj (x) = gj(θj ,x)
and obtain z¯j(x) as gj(θ̂j ,x), where θ̂j is an estimate of a finite-dimensional parameter θj . To take
two examples that commonly come up in genomics, if zj takes values in {0, 1}, e.g. under the dominant
6model, then zj can be modeled using logistic regression, and if zj takes values in {0, 1, 2}, then we
may use a binomial generalized linear model or a proportional odds model. There are two reasons to
prefer to remove the effect of x from z rather than from ξ: first, it may in general be easier to specify
a model for z rather than ξ because of the limited range of z, and, second, this formulation facilitates
asymptotic analysis without the need to derive the asymptotic distributions for the estimated FPCA
scores. Finally, based on {ξ̂ik}Kk=1 and z¯j(xi), our proposed test statistic is
Q =
1
n
∑
j∈S
K∑
k=1
(
n∑
i=1
ξ̂ikẑ
∗
ij
)2
=
∥∥∥∥∥n− 12
n∑
i=1
ξ̂iẑ
∗T
iS
∥∥∥∥∥
2
F
.(7)
where ẑ∗iS = (ẑ
∗
ij1
, ..., ẑ∗ijs)
T and ẑ∗ij = zij − z¯j(xi).
2.2. Connection to mixed effects models. In this section, we demonstrate that one can arrive at the
quantity (4) via a more familiar mixed effects model. Consider the model
yir = µ(tir) +
K∑
k=1
ξikφk(tir) + ir,(8)
ξi = (ξi1, ..., ξiK)
T ∼ N(Bz∗iS ,Λ), ir ∼ N(0, σ2)(9)
where B is a K × s matrix with (k, j)th entry βkj and Λ = diag(λ1, ..., λK). We can obtain Q0 as the
variance component score test statistic for H0 : B = 0. Specifically, let βkj = ηνkj and we consider
a working model such that {νkj} are independently distributed with E(νkj) = 0 and Var(νkj) = λ2k.
Under this working model, H0 : B = 0 is equivalent to
H0 : η = 0.
This formulation follows the logic of variance component score tests that have been proposed previously
[31] and recalls, for example, the likelihood ratio test proposed in [9]. To obtain the variance component
test statistic, rewrite the model as
yµi =
K∑
k=1
∑
j∈S
ηνkjz
∗
ij + eik
φik + i
for centered outcome yµi = {yi1 − µ(ti1), ..., yiri − µ(tiri)}T, error vector i = (i1, ..., iri)T, and random
effects ei = (ei1, ..., eiK)
T ∼ N(0,Λ). Then
yµi|ν, {z∗iS}ni=1 ∼ N
∑
j∈S
K∑
k=1
ηνkjz
∗
ijφik,Σyi

where Σyi =
∑K
k=1 λkφikφ
T
ik + σ
2Iri and Iri is the ri × ri identity matrix.
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The log-likelihood for yµi can then be written
logL(η) = −1
2
n∑
i=1
log |Σyi |+
yµi − η∑
j∈S
K∑
k=1
νkjz
∗
ijφik
T Σ−1yi
yµi − η∑
j∈S
K∑
k=1
νkjz
∗
ijφik
 .
Because the target of inference is η, we marginalize over the nuisance parameter ν conditional on
the observed data to obtain L∗(η) = E{L(η)|V} where the expectation is taken over the distribution
of ν. We follow the argument in [8] and note that the score at the null value is 0: limη→0 ∂ logL∗(η)/∂η =
E
(∑n
i=1 y
T
µiΣ
−1
yi
∑
j∈S
∑K
k=1 νkjz
∗
ijφik | V
)
= 0. So we instead consider the score with respect to η2, limη→0 ∂ logL∗(η)/∂(η2),
and we show in the supplementary article [1] that it can be written
E
{
∂ logL(η)
∂η
∣∣∣∣
η=0
| V
}2
+ E
{
∂2 logL(η)
∂η2
∣∣∣∣
η=0
| V
}
= E
 n∑
i=1
yTµiΣ
−1
yi
∑
j∈S
K∑
k=1
νkjz
∗
ijφik | V
2 − E
 n∑
i=1
∑
j,j′∈S
K∑
k,k′=1
νkjz
∗
ijφ
T
ikΣ
−1
yi νk′j′z
∗
ij′φik′ | V

=
∑
j∈S
K∑
k=1
(
n∑
i=1
yTµiΣ
−1
yi φikλkz
∗
ij
)2
−
∑
j∈S
K∑
k=1
{
n∑
i=1
(λkz
∗
ij)
2φTikΣ
−1
yi φik
}
up to a scaling constant.
To finally obtain Q0, we standardize by n
−1 and drop the second term because it converges to a
constant, yielding the score statistic
n−1
∑
j∈S
K∑
k=1
(
n∑
i=1
yTµiΣ
−1
yi φikλkz
∗
ij
)2
= n−1
∑
j∈S
K∑
k=1
(
n∑
i=1
ξ˜ikz
∗
ij
)2
= Q0,
taking note of the form of ξ˜ik from (3). Thus, our proposed test statistic can be obtained as a variance
component test under a normal mixed model framework. On the other hand, we can also view Q0 as a
simple summary of the overall covariance between the scores of the FPCA and the genetic markers. We
next derive the null distribution of the FPVC test statistic without requiring the normal mixed model
to hold.
2.3. Estimating the null distribution of the test statistic. In order to obtain p-values for FPVC
testing, we must identify the null distribution of Q. To this end, we show in [1] that the key quantity
in Q
qkj = n
− 1
2
n∑
i=1
ξ̂ikẑ
∗
ij
8is asymptotically equivalent to
q˜kj = n
− 1
2
n∑
i=1
ξ˜ikẑ
∗
ij
under H0, i.e. qkj − q˜kj = op(1) for each j and k. The key idea for deriving the null distribution of qkj
is that, since ẑ∗ij is approximately mean 0 conditional on xi, the variability due to approximating ξ˜ik by
ξ̂ik does not contribute any additional noise to qkj (compared to q˜kj) at the first order under H0. Thus,
we can obtain the limiting distribution of Q by analyzing the quantity Q˜ =
∑
j∈S
∑K
k=1 q˜
2
kj .
To characterize the null distribution of Q˜, we need to account for the variability in the estimated
model parameters for µzj (xi) = gj(θj ,xi) in ẑ
∗
ij . Without loss of generality, we assume that for each j
(10) n
1
2 (θ̂j − θj) = n− 12
n∑
i=1
Uj(xi)z∗ij + op(1),
where U(·) is some (q + 1)-dimensional function of xi with E{U(xi)2} <∞. It follows that
qkj = q˜kj + op(1) = n
− 1
2
n∑
i=1
Qikj + op(1)(11)
where Qikj =
{
ξ˜ik − AkjU(xi)
}
z∗ij , Akj = E{ξ˜ikg˙j(θj ,xi)T}, and g˙j(θj ,xi) = ∂gj(θj ,xi)/∂θj . We show
in [1] that the limiting null distribution of Q is a mixture of χ21 random variables, Q ∼
∑sK
l=1 alχ
2
1, with
mixing coefficients determined by the eigenvalues of the covariance matrix of {Qikj}j∈S,1≤k≤K . So finally
we obtain a p-value for the association between the set zS and Y (·) as P (
∑sK
l=1 âlχ
2
1 > Q | V), where âl
is an empirical estimate of al.
By a similar argument, one could construct an asymptotically equivalent test statistic by estimating
ξ˜i in two stages. Instead of obtaining an estimator directly from FPCA via equation (5), FPCA can
be used to estimate only µ(·) and {φk(·)}Kk=1. By plugging the estimated µ̂(·) and {φ̂k(·)}Kk=1 into the
mixed model (8), one can obtain what we will call the re-fitted test statistic
Q¯ = n−1
∑
j∈S
K∑
k=1
[
n∑
i=1
ξ¯ikẑ
∗
ij
]2
(12)
where ξ¯i = (ξ¯i1, ..., ξ¯iK)
T is the BLUP from the model yir− µ̂(tir) =
∑K
k=1 ξikφ̂k(tir)+ir with Cov(ξi) =
D, for some unspecified positive definite matrix D. By the same argument above, estimation of ξ˜ik by
ξ¯ik contributes no additional variability to the test statistic at the first order. It follows that
q†kj = n
− 1
2
n∑
i=1
ξ¯ikẑ
∗
ij = q˜kj + op(1).
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and hence Q¯ has the same limiting null distribution asQ. Not surprisingly, simulation results suggest that
the performance of Q¯ is quite similar to the performance of Q. This equivalence indicates that effectively
our proposed testing procedure uses FPCA to estimate potentially nonlinear bases and assesses the effect
of genetic markers by fitting a mixed model with these basis functions. On the other hand, the test
statistics can also be viewed as a simple summary of covariances, and – since we estimate the null
distribution without relying on the normality assumption required by the mixed models – our testing
procedure remains valid regardless of the adequacy of the mixed model.
2.4. Combining multiple sources of outcome information. In the HIV progression study, we seek to
test the overall association between SNPs and both lCD4 and lVL simultaneously because more and
distinct information about HIV progression is captured in both measures than in either one alone. FPVC
testing, as outlined above, can be easily adapted to perform a test for the overall association between zS
and all outcomes of interest. To use information in multiple outcomes, {y(m)}Mm=1, we simply perform
FPCA separately on each y(m) and obtain FPCA scores for each person and each outcome. Subject i’s
scores for y
(m)
i would be ξ̂
(m)
i = (ξ̂
(m)
i1 , ..., ξ̂
(m)
iKm
)T, as in (5), and the full set of scores for person i would
be ξ̂i = (ξ̂
(1)T
i , ..., ξ̂
(m)T
i )
T. Then we simply proceed by testing
H0 : {y(m)}Mm=1 ⊥ zS | x
as before based on
Q = ‖n− 12
n∑
i=1
ξ̂iẑ
∗T
iS‖2F =
M∑
m=1
‖n− 12
n∑
i=1
ξ̂
(m)
i ẑ
∗T
iS‖2F .(13)
Since each outcome may be measured on a different scale, one may use scaling or weighting to allow
scores from each outcome to contribute similarly to the test statistic. See section 5 for further discussion
of scaling/weighting.
3. Association study for HIV progression. In this study, two independent cohorts were re-
cruited in Botswana to detect sets of SNPs related to HIV disease progression as measured by lCD4 and
lVL. The first cohort, which we will denote BHP010, was a natural history observational prospective
cohort study recruited from clinics in Gaborone. This cohort included HIV-1C-infected individuals with
CD4 cell counts above 400 cells per µl and not yet qualified for the Botswana highly active antiretroviral
treatment (HAART) program. Patients were not enrolled if they were younger than 18, had an active
AIDS-defining illness requiring the initiation of HAART, presented with an AIDS-related malignancy,
or had previously been exposed to HAART during pregnancy or breast feeding.
Follow-up visits occurred at approximately three-month intervals with an additional visit one month
after enrollment. VL was generally collected at six-month intervals, and most patients in this cohort
do not have VL measurements after two years of follow-up. Follow-up began in 2005 and lasted for up
to 255 weeks. The mean follow-up time was 41 months. At least two CD4 measurements were required
for measuring disease progression, and 449 patients satisfied this criterion. Of these, the median age at
10
baseline was 34 years old with an interquartile range (IQR) of (28, 39). There were 366 women. In 2008,
143 patients were genotyped on an Illumina LCG BeadChip, the chip used in the second cohort. After
making exclusions for quality control – call rate greater than 0.99, gender matching listed gender – 137
individuals were included in the association study.
The second cohort we will denote BHP011. This cohort came from a randomized, multifactorial,
double-blind placebo-controlled trial conducted between December 2004 and July 2009 [3]. The pur-
pose of the trial was to determine the efficacy of micronutrient supplementation (supplementation of
multivitamin, selenium, or both) in improving immune function in HIV-1C-infected individuals. It was
composed of 878 treatment-naive patients with CD4 higher than 350 cells/µl, as well as body mass
index (BMI) greater than 18 for women and 18.5 for men (calculated as weight in kilograms divided by
height in meters squared), age of 18 years or older, no current AIDS-defining conditions or history of
AIDS-defining conditions, and no history of endocrine or psychiatric disorders.
Patients were followed up for a maximum of 169 weeks. They returned to clinics approximately every
3 months to measure CD4 and approximately every 6 months to measure VL. The mean follow-up
time was 696 days. Of these, 838 had at least two CD4 measurements, of whom 613 were women. The
median age at baseline was 33 years old with an interquartile range (IQR) of (28, 39). In this cohort, 326
individuals were genotyped on Illumina LCG BeadChips, with 320 entered into the association study
after quality control exclusions.
FPCA was performed on each cohort separately for both lCD4 and lVL. Three eigenfunctions were
chosen for lCD4 and two for lVL in each cohort, which corresponds to 99% of proportion of variance
explained for each. The form of the eigenfunctions look similar for both lCD4 and lVL in each cohort
and lend themselves to reasonable interpretations. The first eigenfunction tends to serve as a mean
shift or an intercept; the second eigenfunction acts something like a slope; and the third eigenfunction
behaves approximately as a quadratic term. The vector of estimated ”re-fitted” scores (refer to (12)) for
each individual to be used in testing can be written ξ̂i = (ξ̂
(m)
ik )k=1,2,3;m=1,2 where ξ̂
(m)
ik is the estimated
score corresponding to the kth estimated eigenfunction of lCD4 when m = 1 and lVL when m = 2.
A total of 155,007 SNPs on chromosome 6 were genotyped. After requiring less than 5% missingness
and at least five individuals with any minor alleles in each cohort, p = 108, 665 SNPs, zi = (zi1, ..., zip)
remained for association testing, where the ordering in zi corresponds to position on the chromosome.
The dominant model was used for analysis such that zij = 1 if any minor alleles are present and zij =
0 if none are present. Missing values were imputed as the minor allele frequency for that SNP. In order
to gain power by pooling information in nearby SNPs, sets of 10 contiguous SNPs were constructed as
ziSj = (zij , ..., zij+9) for j = 1, ..., 108, 656. Here the choice of 10 merely serves as example for illustration
and sets could in principle be constructed with more SNPs, but due to the small sample size in each
cohort, we kept the size of the sets modest. Tests were performed on each cohort separately, and p-
values were combined using the Fisher method. The false discovery rate was controlled at 0.1 using the
Benjamini-Hochberg procedure [4], which is expected to remain valid since although the moving window
construction of sets induces high correlations for nearby regions, SNP sets in distant regions are not
expected to be correlated [28].
Tests were adjusted for age and gender to remove any possible confounding, so that we are testing
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Fig 1. Manhattan plot for set-based testing on chromosome 6. Position on x-axis for each test is determined by the middle
SNP (5th of 10) in the set. The dotted line corresponds to the threshold for rejection at FDR 0.1.
for the effect of SNP sets on disease progression conditional on age and gender. Logistic regression was
used to remove their effect. The method appears to be robust to this specification, as results were not
markedly changed either when no adjustment was made or by specifying a probit model (results not
shown).
The manhattan plot for the 108,656 tests is given in figure 1. In all, 126 tests passed the FDR
threshold, corresponding to 4 broad regions of the chromosome. Six contiguous tests rejected in the
region between positions 6,784,416 and 6,793,116 (region 1), which fall between the LY86 and BTF3P7
genes; 117 tests rejected between positions 31,022,266 and 31,080,899 (region 2), including SNPs on the
HCG22 and C6orf15 genes; two tests rejected between 122,990,817 and 123,014,708 (region 3) on the
PKIB gene; and one test rejected representing SNPs in the region between 162,250,522 and 162,254,546
(region 4) including SNPs on the PARK2 gene. Notably, the C6orf15 gene has been reported to be
associated with susceptibility to follicular lymphoma [27], and genes in linkage disequilibrium with
HCG22 and C6orf15 have demonstrated associations to total white blood cell counts [21] and multiple
myeloma [7].
Furthermore, regions 1, 3, and 4 – whose -log10 p-values are depicted in figure 2 (a), (c), and (d),
respectively – only have strong signals in one of the two cohorts. Region 1 demonstrates association
largely in BHP010, as can be seen in the figure where the large triangles in the figure (representing
the set-based p-value in BHP010) tend to lie above the large dots (representing the combined set-based
p-value), while the diamonds for BHP011 tend to be very low. Conversely, in regions 3 and 4 the
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association is apparent only in BHP011. Whereas in region 2, associations tend to be strong in both
cohorts, and the combined p-values tend to be lower (higher in the figure) than either of the component
p-values.
To get a better sense of what the test is picking up on, we looked at average disease progression
within groups of patients with similar minor allele burden. To do this, we identified the SNP set with
the smallest p-value, which lay in the HCG22 portion of region 2 and included the following SNPs:
rs2535308, rs2535307, rs2535306, rs2535305, rs3130955, rs2535304, rs12527394, rs2535303, kgp9442190,
and rs3130959. Patients were grouped according to the number of loci among these 10 at which they
had any minor alleles. Within these groups, we averaged the estimated mean lCD4 and lVL in each
cohort over time Ŷ (·) = µ̂(·) +∑Kk=1 ξ̂ikφ̂k(·). As a demonstration, the results for those with 2, 3, 8,
and 9 loci with minor alleles are depicted in figure 3. We selected these groups to demonstrate burden
extremes (very few individuals had 0 or 1 loci affected, so they were not shown).
Those with only 2 and 3 affected loci looked to generally be the healthiest group, having higher and
more stable CD4 and lower and gently increasing VL throughout the study period in each cohort. Those
with 3 affected loci tended to have a more negative CD4 slope and higher and increasing VL over the
study period. Those with 9 affected loci in general had the worst progression: low and declining CD4
counts in both cohorts, and high and relatively stable VL in both cohorts. Those with 8 affected loci
tend to fall in the middle. Smoothing the raw data directly in each of these groups yielded similar results
and nearly identical conclusions (results not shown).
4. Simulation results. We have performed simulation studies to assess the finite sample perfor-
mance of our proposed testing procedure and compare its power to the standard linear-mixed-model-
based procedures. For simplicity, we focused on a single marker z in the absence of covariates and two
potential functional outcomes generated from
y
(m)
ir = Y
(m)
i (tir) + 
(m)
ir
= sin(tir) + (−1)m−1γ {sin(tir/3) + cos(tir)}+ (1− γ)
{
bi0 + 0.5b
(m)
i1 cos(tir/4)
}
+
βzi {α (cos(tir) + cos(tir/10)− sin(3tir)) + (1− α)tir/7}+ (m)ir , m = 1, 2,
where b
(m)
ij ∼ N(0, 0.25), j = 0, 1 are independent and identically distributed (iid) random effects and

(m)
ir ∼ N(0, 0.25) are iid errors, for m = 1, 2. For each subject i, we generate the number of observations
from a Poisson distribution ri ∼ Poisson(λ) + 2, and we generate tir uniformly over the time interval
(0, 2pi). The parameter β controls the magnitude of the genetic effect. The parameter α controls how
linear the genetic affect is – when α = 0 the genetic effect is entirely linear, and when α = 1 the effect
is entirely nonlinear. On the other hand, γ controls the complexity of the mean process and the amount
of inter-subject variability – when γ = 0, the mean process is relatively simple but the inter-subject
variability is high, and when γ = 1 the mean process is complex and the inter-subject variability is low.
The genetic factor zi is generated according to a binomial(2, 0.1), with 0.1 the minor allele frequency.
We examined the performance of the FPVC test statistic Q (defined in (13), here denoted by “FPCA”)
and its asymptotically equivalent counterpart Q¯ (defined in the context of a single outcome in (12), here
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(a) (b)
(c) (d)
Fig 2. P-values in significant regions on the -log10 scale. Large symbols correspond to set-based tests, and for illustration
small symbols correspond to tests for individual SNPs. Triangles represent p-values computed in BHP010, and diamonds
BHP011. Circles represent combined set-based p-values, which are of primary interest and are connected by lines. Combined
p-values that are below the FDR threshold are in color, as are their corresponding component p-values.
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(a) (b)
(c) (d)
Fig 3. Disease progression by minor allele burden in most significant SNP set. Estimated lCD4 and lVL are grouped by
number of loci in SNP set with any minor alleles and averaged. For clarity, just those individuals with 2, 3, 8, and 9 loci
are included. Lines correspond to estimates of the conditional mean based on FPCA.
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denoted ”Re-fitted”). For the purposes of comparison, we also examined the performance of a similar
test statistic that does not use FPVC but instead employs a pre-specified basis. Consider the test
statistic Qlin =
1
n
∑2
m=1
∑2
k=1
[∑n
i=1 ξ
(m)†
ik ẑ
∗
i
]2
, where ξ
(m)†
ik is the BLUP from the linear mixed model
yir = β0 + β1tir + ξi1 + ξi2tir + ir. In the following, we denote results for Qlin by ”Linear”.
The number of FPCA scores for the mth outcome, Km, was selected as the smallest K such that the
fraction of variation explained (FVE),
∑K
k=1 λ̂k/(
∑
k λ̂k), was at least ℘ = 0.99. To ensure that the scores
for each outcome contributed comparably to the test statistics, we centered and scaled each outcome as
y
∗(m)
ir = (y
(m)
ir −y¯(m))/σ̂(m)y , prior to obtaining ξ̂(m)ik and ξ(m)†ik , where σ̂(m)y =
√
(n− 1)−1∑i,r(y(m)ir − y¯(m))2
and y¯(m) = n−1
∑
i,r y
(m)
ir .
In the following we report power as the proportion of 1000 simulations for which the testing procedure
produced a p-value below 0.05 to demonstrate the relative performance of the various testing procedures.
To ensure that the asymptotic null distribution of the test statistic yields a valid testing procedure, we
evaluate the entire distribution of p-values under the null hypothesis, including at levels much lower
than 0.05.
4.1. Type I error. In the following we take λ = 6. The empirical type I error rates for testing at
the 0.05 level ranged from 0.040 (γ = 0.25) to 0.048 (γ = 0) for Q; from 0.036 (γ = 1) to 0.047
(γ = 0) for Q¯; and from 0.040 (γ = 0.75) to 0.059 (γ = 1) for Qlin. However, levels much smaller
than 0.05 are necessary to control error rates in large-scale testing. Thus, in order to establish the
validity of our testing procedure for performing many tests, we establish that the resulting p-values are
approximately uniform under the null hypothesis. We performed 106 simulations under the null, with
n = 200, γ = 1, and α = 0, and we obtained the type I error of FPVC testing at each of the following
levels: 1× 10−6, ..., 9× 10−6, 1× 10−5, ..., 9× 10−5, 1× 10−4, ..., 9× 10−4, 1× 10−3, ..., 9× 10−3. Results
are depicted in Figure 4. The Figure shows that the level is preserved at all levels of testing. Further
simulations would provide better approximations of type I error rates at smaller levels, but these results
suggest that the asymptotic null distribution fits quite well in small samples.
4.2. Power. In figure 5, we display results for n = 100 and all levels of γ and α. There, the figure
demonstrates that, despite the fact that the true effect was linear when α = 0, both FPC-based tests
dominate the linear-based tests, and the advantage of using FPVC, in terms of power, did not disappear,
even when the true effect was linear. Notably, as γ varied, we saw power gains by using the FPVC-based
Q and Q¯, with the gains increasing as γ approached 1 and the functional form of Y
(m)
i (·) became more
complex, and the need to flexibly model it increased.
In all of our simulations, the FPVC methods dominated the linear method in terms of power while
maintaining desirable type I error rates. We wanted to ensure that the improvement we were seeing was
not simply due to the fact that the linear model used only two scores, a random intercept ξ
(m)†
i1 and a
random slope ξ
(m)†
i2 , for each outcome whereas the FPVC-based methods used Km scores, where Km
was often selected larger than 2. Thus, we also considered the performance of scores based on fixed-basis
expansions of t, using either polynomial or spline bases.
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Fig 4. Empirical type I error rates for tests performed at various levels, based on 106 simulations.
Specifically, we fit models with K = 2, 3, ..., 6 degrees of freedom. For polynomial bases corresponded
to the model yir =
∑K
k=1(βk+ξik)t˜
k−1
ir +ir for t˜ir a centered and scaled version of tir. And for the spline
basis, we used cubic B-splines constructed with the specified degrees of freedom with the bs function in
the splines R package. Because, in some sense, FPCA does model selection by choosing the basis that
explains the most variability in y, we also perform model selection on the pre-specified bases in order
to make the comparison fair. We select the model with the lowest AIC and use the ξ̂iks from that model
in the testing procedure. We will call the test statistic based on B-splines QB and the model based on
polynomial bases Qp.
Results are found in figure 6. We found that there were some situations when using the pre-specified
B-spline basis could outperform the FPVC tests, particularly when γ was near 0 (low mean complexity)
and α was near 1 (linear genetic effect). However, the polynomial basis never outperformed FPVC.
And as the complexity of the trajectory γ increased, the desirability of FPVC testing always increased.
This suggests that in simple problems, using a pre-specified basis may be preferable, but for complex
effects and complex trajectories, FPVC will likely be preferred. And in general, if the complexity of
the trajectory is unknown, FPVC testing offers a generally powerful method for all settings that is
insensitive to tuning parameter selection.
5. Discussion. We have proposed functional principal variance component testing, a FPCA-based
testing procedure for assessing the association between a set of genetic variants zS and a complexly
varying longitudinal outcome y that is feasible on the genome-wide scale, allowing adjustment for
other covariates. Unlike the standard mixed-model-based approaches, we do not model the trajectories
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Fig 5. Power to detect β using Q (FPVC), Q¯ (FPVC Re-fitted), and Qlin (Linear).
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Fig 6. Power to detect β using Q (FPVC), QB (B-splines), and Qp (Polynomial).
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{Yi(·)}ni=1 parametrically but use the data to identify the most parsimonious summaries of the trajectory
patterns via FPCA. We subsequently test the association between the random coefficients ξi and the
markers of interest using a test statistic motivated by variance component testing. Our procedure could
potentially be much more powerful than procedures based on pre-specified bases, which might suffer
power loss due to either high degrees of freedom or inability to capture the complexity in the trajectories.
Furthermore, our FPVC testing is computationally efficient as we are able to perform thousands or even
millions of tests quickly by separating the time-intensive FPCA from the testing. This makes our method
feasible on the genome-wide scale where millions of marginal tests may be necessary. As an example,
computing test statistics and p-values for FPVC testing typically takes less than 0.1 seconds for a set
of 10 SNPs and both lCD4 and lVL combined. On the other hand, fitting a single linear mixed effects
model for only lCD4 with a random effect for a small pre-specified B-spline basis takes more than 2
seconds. At the genome-wide scale we would observe a speed-up on the order of hours. Code for FPVC
testing is available at https://github.com/denisagniel/fpvc.
It is important to note that while we make mild assumptions on the longitudinal outcome y to obtain
the form of our proposed test statistic, the validity of FPVC testing requires no assumption about the
relationship between y and zS . FPVC testing remains valid even if the working mixed model (8) fails to
hold. Additionally, while one can motivate the quantity ξ˜ik as the conditional expectation of ξik under a
normality assumption on ξik and ir, even when this normality fails to hold, testing based on Q remains
valid since the estimated eigenvalues and eigenfunctions from functional PCA are uniformly convergent
to their limits [13]. In fact, one can consider FPVC model-free in that the test statistic Q could be
motivated simply as an estimated covariance. Furthermore, we assume that the errors ir are iid with
mean 0 and variance σ2, but some relaxation of this assumption is possible for some ”degree of weak
dependence and in cases of non-identical distribution” [13], while still maintaining the validity of our
procedure.
FPVC testing can also simultaneously consider multiple sources of outcome information to better
characterize complex phenotypes. With multiple longitudinal outcomes, one might wish to ensure that
scores for all outcomes are roughly on the same scale, so that each outcome contributes comparably to
the test statistic. To this end, one may consider a weighted version of (13) as
Q =
M∑
m=1
ωm‖n− 12
n∑
i=1
ξ̂iẑ
∗
iS‖2F ,
where ωm are nonnegative outcome-specific weights that can be pre-specified or data adaptive. Al-
ternatively, in the absence of relevant weights, one can simply scale each y(m) so that the mag-
nitude of ξ̂
(m)
i is comparable across different values of m. Let y
∗(m)
ir = y
(m)
ir /σ̂
(m)
y where σ̂
(m)
y =√
(n− 1)−1∑i,r(y(m)ir − y¯(m))2 and y¯(m) = n−1∑i,r y(m)ir . Then obtain ξ̂∗(m)i via FPCA on {y∗(m)i }ni=1
and construct the test statistic
∑M
m=1 ‖n−
1
2
∑n
i=1 ξ̂
∗(m)
i ẑ
∗
iS‖2F . Such a strategy appears to work well in
simulation studies.
While we use FPCA to summarize the longitudinal trajectories for the purpose of testing with low
degrees of freedom, in principle another suitably parsimonious nonparametric method could be used
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instead. For example, if observations were measured on a common, fine grid of points, then one could
imagine using the methods in [20] to first regress y on t, obtain the random effects estimates (similar
to the ξi employed here), and use these in testing. However, no available approaches are as widely
applicable as our FPCA-based approach, which can be used even when data are sparsely observed;
other approaches may not have as small effective degrees of freedom as an FPCA-based method, and
the resulting testing procedure may be more sensitive to correct tuning.
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